Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.08
EW's Cash-to-Debt is ranked lower than
58% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. EW: 1.08 )
Ranked among companies with meaningful Cash-to-Debt only.
EW' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 1.42 Max: N/A
Current: 1.08
Equity-to-Asset 0.57
EW's Equity-to-Asset is ranked lower than
57% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. EW: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
EW' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.61 Max: 0.85
Current: 0.57
0.4
0.85
Interest Coverage 105.14
EW's Interest Coverage is ranked higher than
50% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. EW: 105.14 )
Ranked among companies with meaningful Interest Coverage only.
EW' s Interest Coverage Range Over the Past 10 Years
Min: 18.97  Med: 63.1 Max: 118.46
Current: 105.14
18.97
118.46
Piotroski F-Score: 5
Altman Z-Score: 9.17
Beneish M-Score: -2.43
WACC vs ROIC
7.43%
31.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 28.04
EW's Operating Margin % is ranked higher than
95% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. EW: 28.04 )
Ranked among companies with meaningful Operating Margin % only.
EW' s Operating Margin % Range Over the Past 10 Years
Min: 13.99  Med: 22.1 Max: 53.09
Current: 28.04
13.99
53.09
Net Margin % 20.85
EW's Net Margin % is ranked higher than
92% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. EW: 20.85 )
Ranked among companies with meaningful Net Margin % only.
EW' s Net Margin % Range Over the Past 10 Years
Min: 10.36  Med: 16.35 Max: 34.92
Current: 20.85
10.36
34.92
ROE % 25.60
EW's ROE % is ranked higher than
91% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. EW: 25.60 )
Ranked among companies with meaningful ROE % only.
EW' s ROE % Range Over the Past 10 Years
Min: 14.26  Med: 20.89 Max: 43.42
Current: 25.6
14.26
43.42
ROA % 15.25
EW's ROA % is ranked higher than
92% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. EW: 15.25 )
Ranked among companies with meaningful ROA % only.
EW' s ROA % Range Over the Past 10 Years
Min: 8.72  Med: 13.18 Max: 26.03
Current: 15.25
8.72
26.03
ROC (Joel Greenblatt) % 85.94
EW's ROC (Joel Greenblatt) % is ranked higher than
93% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. EW: 85.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EW' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.35  Med: 57.83 Max: 138.73
Current: 85.94
41.35
138.73
3-Year Revenue Growth Rate 14.80
EW's 3-Year Revenue Growth Rate is ranked higher than
80% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. EW: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
EW' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 11.5 Max: 15.1
Current: 14.8
-9.7
15.1
3-Year EBITDA Growth Rate 14.00
EW's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. EW: 14.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EW' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.2  Med: 16 Max: 57.8
Current: 14
-20.2
57.8
3-Year EPS without NRI Growth Rate 15.10
EW's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. EW: 15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EW' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 20.85 Max: 288.2
Current: 15.1
0
288.2
GuruFocus has detected 3 Warning Signs with Edwards Lifesciences Corp $EW.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EW's 10-Y Financials

Financials (Next Earnings Date: 2017-07-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EW Guru Trades in Q1 2016

Ray Dalio 18,800 sh (New)
Jim Simons 1,665,800 sh (+50.74%)
Pioneer Investments 1,716,295 sh (+8.75%)
RS Investment Management 182,175 sh (+8.23%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Louis Moore Bacon Sold Out
Frank Sands 10,172,988 sh (-6.88%)
Ron Baron 528,665 sh (-20.41%)
Jeremy Grantham 149,328 sh (-30.58%)
Paul Tudor Jones 2,600 sh (-73.60%)
Steven Cohen 13,700 sh (-90.85%)
» More
Q2 2016

EW Guru Trades in Q2 2016

Lee Ainslie 32,300 sh (New)
Joel Greenblatt 5,837 sh (New)
Louis Moore Bacon 2,323 sh (New)
Eaton Vance Worldwide Health Sciences Fund 175,800 sh (New)
Steven Cohen 194,200 sh (+1317.52%)
Paul Tudor Jones 16,686 sh (+541.77%)
Ray Dalio 33,800 sh (+79.79%)
Jim Simons 2,213,800 sh (+32.90%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jeremy Grantham Sold Out
Pioneer Investments 1,703,864 sh (-0.72%)
Frank Sands 9,619,255 sh (-5.44%)
RS Investment Management 91,090 sh (-50.00%)
Ron Baron 30,903 sh (-94.15%)
» More
Q3 2016

EW Guru Trades in Q3 2016

Steven Cohen 337,900 sh (+74.00%)
Louis Moore Bacon 3,570 sh (+53.68%)
Ray Dalio 45,065 sh (+33.33%)
Pioneer Investments 1,762,534 sh (+3.44%)
Eaton Vance Worldwide Health Sciences Fund 213,257 sh (+21.31%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Frank Sands 9,035,637 sh (-6.07%)
Lee Ainslie 26,900 sh (-16.72%)
Jim Simons 1,476,406 sh (-33.31%)
Ron Baron 10,762 sh (-65.17%)
» More
Q4 2016

EW Guru Trades in Q4 2016

Ron Baron 40,284 sh (+274.32%)
Lee Ainslie 38,440 sh (+42.90%)
Steven Cohen 476,400 sh (+40.99%)
Eaton Vance Worldwide Health Sciences Fund 269,163 sh (+26.22%)
PRIMECAP Management 560,000 sh (unchged)
Ray Dalio Sold Out
John Hussman Sold Out
Frank Sands 8,327,338 sh (-7.84%)
Pioneer Investments 1,512,359 sh (-14.19%)
Jim Simons 865,200 sh (-41.40%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:STJ, NYSE:ZBH, OTCPK:SNNUF, NAS:ISRG, NAS:ALGN, OTCPK:SONVY, NYSE:TFX, NYSE:VAR, NYSE:BSX, OTCPK:CNVVY, OTCPK:SDMHF, OTCPK:CHEOY, NAS:ABMD, OTCPK:WILYY, NAS:MASI, NAS:NUVA, OTCPK:FSPKF, OTCPK:EKTAY, OTCPK:GGNDF, NAS:WMGI » details
Traded in other countries:EWL.Germany, EW.Switzerland,
Headquarter Location:USA
Edwards Lifesciences Corp technologies treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of heart disease. Its key products include tissue heart valves, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Guru Investment Theses on Edwards Lifesciences Corp

David Rolfe Comments on Edwards Lifesciences - Apr 14, 2017

We established a new position in Edwards Lifesciences (NYSE:EW) in the first quarter. Edwards is a pioneer in heart valve surgery, with nearly 90% of its revenues tied to heart valve replacement, by virtue of its best-in-class portfolio of intellectual property, backed by a relatively lengthy history of clinical data and successful outcomes. Heart disease is the world’s leading killer, and the incidence of heart disease grows with age, meaning that the aging of populations across the developed world is directly leading to a rise in the occurrence of heart problems. Over half of the Company’s business is tied to the rapidly-growing TAVR, or Transcatheter Aortic Valve Replacement, category. TAVR—as opposed to SAVR, which is Surgical Aortic Valve Replacement, which is generally a type of open-heart surgery—is a fairly recent technological advancement, with the first human procedure occurring in 2002; the first market approval in Europe in 2007; and US approval in 2011. We view TAVR, which replaces a heart valve using a small incision, usually in a patient’s leg, as clearly superior to traditional open-heart surgery, with similar clinical results at a comparable price, but without the need to crack open a patient’s chest. As the market for TAVR has developed, it was first approved for patients for whom traditional surgery was too risky to be a viable option, followed by patients for whom surgery was considered a high risk. 2016 saw a surge in procedures as TAVR was approved for patients for whom surgery is an intermediate risk, and clinical trials are underway to seek approval for low-risk patients, as well.

EW is the clear market leader in the TAVR segment of the market, and we expect its TAVR solutions to continue to gain significant share industry-wide over time as the procedure spreads into the low-risk patient population, especially as regulatory issues constraining the growth of the procedure ease over time, and as the industry invests in patient and physician education to expand the overall valve-replacement population, well beyond prior expectations. In addition, there are a significant amount of underserved populations among patients not yet showing symptoms and patients who might not have considered treatment previously, when the only option was to have their chests cracked open. We believe, over time, that TAVR’s superior, much less invasive treatment option could lead to earlier screening of asymptomatic patients, as well as to patients proactively inquiring about therapy.

On the valuation front, the stock looks attractive in relation to peers and the broader market, having pulled back almost a third from its highs, down to the middle of its historical valuation range, after the past few quarters of earnings results slightly underperformed versus very high expectations. Specifically, there was a temporary issue with France running out of money in its budget for TAVR reimbursement, as the budget had not anticipated the tremendous growth in TAVR procedures for intermediate-risk patients. We view this as a non-issue, longer-term. Further, the sequential growth rate for TAVR revenues slowed in the second half of 2016, despite a continuation of extremely healthy year-over-year growth, which registered nearly 30% globally and nearly 40% in the US in the fourth quarter, for example. We view this as very attractive growth and understand that there will be fits and starts in sequential growth rates around product approval cycles. Longer-term, we view Edwards as an attractive growth opportunity, as aging populations lead to increasing heart disease, and as TAVR takes share within the valve-replacement market. We see opportunities for growth within the established patient population, in addition to current estimates of the patient population that we think are significantly understated, meaning that the market’s long-term growth expectations are also understated. We believe the under-appreciated growth opportunities, the secular shift towards less invasive procedures, and the reasonable valuation makes EW an attractive long-term holding.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners first-quarter 2017 shareholder letter.

Check out David Rolfe latest stock trades

Baron Opportunity Fund Comments on Edwards - Feb 21, 2017

Edwards (NYSE:EW) is the world’s leading manufacturer of tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. Edwards has leveraged the knowledge and experience from its surgical tissue heart valve business to develop transcatheter heart valve replacement technologies, designed to treat heart valve disease using catheter-based approaches as opposed to open surgery. Transcatheter aortic valve replacement (TAVR) is an innovative procedure in which a valve is inserted through a catheter and implanted within the diseased aortic valve. The procedure is significantly less invasive than surgery, takes about 90 minutes and recovery can be as short as a few days. TAVR is transforming the market because it provides a new, less invasive treatment option for patients ineligible for surgery or at high surgical risk. Edwards believes there are about 650,000 aortic stenosis patients addressable with TAVR–over twice their prior view of the addressable market–only a fraction of which are being treated with TAVR today. Edwards is also investing in transcatheter valve technologies to treat patients with mitral and tricuspid diseases–which present large, untapped addressable markets (2.5 million for mitral and 1.5 million for tricuspid)–and have the potential to open up significant new growth opportunities for the company.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Edwards Lifesciences Corp

David Rolfe Comments on Edwards Lifesciences Guru stock highlight
We established a new position in Edwards Lifesciences (NYSE:EW) in the first quarter. Edwards is a pioneer in heart valve surgery, with nearly 90% of its revenues tied to heart valve replacement, by virtue of its best-in-class portfolio of intellectual property, backed by a relatively lengthy history of clinical data and successful outcomes. Heart disease is the world’s leading killer, and the incidence of heart disease grows with age, meaning that the aging of populations across the developed world is directly leading to a rise in the occurrence of heart problems. Over half of the Company’s business is tied to the rapidly-growing TAVR, or Transcatheter Aortic Valve Replacement, category. TAVR—as opposed to SAVR, which is Surgical Aortic Valve Replacement, which is generally a type of open-heart surgery—is a fairly recent technological advancement, with the first human procedure occurring in 2002; the first market approval in Europe in 2007; and US approval in 2011. We view TAVR, which replaces a heart valve using a small incision, usually in a patient’s leg, as clearly superior to traditional open-heart surgery, with similar Read more...
Baron Opportunity Fund Comments on Edwards Guru stock highlight
Edwards (NYSE:EW) is the world’s leading manufacturer of tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. Edwards has leveraged the knowledge and experience from its surgical tissue heart valve business to develop transcatheter heart valve replacement technologies, designed to treat heart valve disease using catheter-based approaches as opposed to open surgery. Transcatheter aortic valve replacement (TAVR) is an innovative procedure in which a valve is inserted through a catheter and implanted within the diseased aortic valve. The procedure is significantly less invasive than surgery, takes about 90 minutes and recovery can be as short as a few days. TAVR is transforming the market because it provides a new, less invasive treatment option for patients ineligible for surgery or at high surgical risk. Edwards believes there are about 650,000 aortic stenosis patients addressable with TAVR–over twice their prior view of the addressable market–only a fraction of which are being treated with TAVR today. Edwards is also investing in transcatheter valve technologies to treat patients with mitral and tricuspid diseases–which Read more...
Edwards Lifesciences Director Buys 3,000 Shares Company increased revenue and gross profits at a solid rate over the last 10 years
Kieran Gallahue, director of Edwards Lifesciences (NYSE:EW), purchased 3,000 shares of the company for $90.10 per share on Feb. 3 according to a Form 4 filing with the Securities and Exchange Commission. He now owns 9,042 shares of the company. Read more...
Numerous Companies Reach Yearly Highs Recently, a handful of companies achieved 52-week highs
According to GuruFocus list of 52-week highs, these stocks have reached their 52-week highs. Read more...
Vanguard Sells Out Edwards Lifesciences Company's price and P/E ratio near 10-year highs
Vanguard Heath Care Fund sold out its stake in Edwards Lifesciences Corp. (NYSE:EW) in the first quarter. Read more...

Ratios

vs
industry
vs
history
PE Ratio 36.29
EW's PE Ratio is ranked lower than
59% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. EW: 36.29 )
Ranked among companies with meaningful PE Ratio only.
EW' s PE Ratio Range Over the Past 10 Years
Min: 11.18  Med: 27.89 Max: 50.58
Current: 36.29
11.18
50.58
Forward PE Ratio 32.26
EW's Forward PE Ratio is ranked lower than
69% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. EW: 32.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 36.29
EW's PE Ratio without NRI is ranked lower than
60% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. EW: 36.29 )
Ranked among companies with meaningful PE Ratio without NRI only.
EW' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.16  Med: 27.78 Max: 49.62
Current: 36.29
11.16
49.62
Price-to-Owner-Earnings 44.32
EW's Price-to-Owner-Earnings is ranked lower than
60% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. EW: 44.32 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
EW' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.88  Med: 35.35 Max: 572.5
Current: 44.32
7.88
572.5
PB Ratio 8.40
EW's PB Ratio is ranked lower than
83% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. EW: 8.40 )
Ranked among companies with meaningful PB Ratio only.
EW' s PB Ratio Range Over the Past 10 Years
Min: 2.9  Med: 5.62 Max: 10.16
Current: 8.4
2.9
10.16
PS Ratio 8.02
EW's PS Ratio is ranked lower than
76% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. EW: 8.02 )
Ranked among companies with meaningful PS Ratio only.
EW' s PS Ratio Range Over the Past 10 Years
Min: 2.32  Med: 4.72 Max: 9.41
Current: 8.02
2.32
9.41
Price-to-Free-Cash-Flow 48.82
EW's Price-to-Free-Cash-Flow is ranked lower than
67% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. EW: 48.82 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
EW' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.83  Med: 38.58 Max: 593.7
Current: 48.82
7.83
593.7
Price-to-Operating-Cash-Flow 33.77
EW's Price-to-Operating-Cash-Flow is ranked lower than
69% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. EW: 33.77 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
EW' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.34  Med: 27.04 Max: 48.74
Current: 33.77
7.34
48.74
EV-to-EBIT 22.69
EW's EV-to-EBIT is ranked lower than
54% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. EW: 22.69 )
Ranked among companies with meaningful EV-to-EBIT only.
EW' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 20.7 Max: 39.7
Current: 22.69
6.8
39.7
EV-to-EBITDA 21.31
EW's EV-to-EBITDA is ranked lower than
63% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. EW: 21.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
EW' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 16.4 Max: 33.5
Current: 21.31
6.4
33.5
PEG Ratio 1.83
EW's PEG Ratio is ranked higher than
65% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.52 vs. EW: 1.83 )
Ranked among companies with meaningful PEG Ratio only.
EW' s PEG Ratio Range Over the Past 10 Years
Min: 0.45  Med: 1.37 Max: 3.46
Current: 1.83
0.45
3.46
Shiller PE Ratio 67.19
EW's Shiller PE Ratio is ranked lower than
56% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. EW: 67.19 )
Ranked among companies with meaningful Shiller PE Ratio only.
EW' s Shiller PE Ratio Range Over the Past 10 Years
Min: 34.67  Med: 61.15 Max: 124.24
Current: 67.19
34.67
124.24
Current Ratio 4.21
EW's Current Ratio is ranked higher than
75% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. EW: 4.21 )
Ranked among companies with meaningful Current Ratio only.
EW' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.67 Max: 5.24
Current: 4.21
1.26
5.24
Quick Ratio 3.46
EW's Quick Ratio is ranked higher than
75% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. EW: 3.46 )
Ranked among companies with meaningful Quick Ratio only.
EW' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.03 Max: 4.54
Current: 3.46
0.9
4.54
Days Inventory 171.23
EW's Days Inventory is ranked lower than
66% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. EW: 171.23 )
Ranked among companies with meaningful Days Inventory only.
EW' s Days Inventory Range Over the Past 10 Years
Min: 132.4  Med: 170.89 Max: 208.39
Current: 171.23
132.4
208.39
Days Sales Outstanding 59.12
EW's Days Sales Outstanding is ranked higher than
83% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. EW: 59.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
EW' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.74  Med: 54.46 Max: 69.95
Current: 59.12
38.74
69.95
Days Payable 42.56
EW's Days Payable is ranked lower than
65% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. EW: 42.56 )
Ranked among companies with meaningful Days Payable only.
EW' s Days Payable Range Over the Past 10 Years
Min: 33.96  Med: 45.59 Max: 63.34
Current: 42.56
33.96
63.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.70
EW's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. EW: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EW' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0.5 Max: 2.2
Current: 0.7
-1.2
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 16.71
EW's Price-to-Tangible-Book is ranked lower than
81% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. EW: 16.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
EW' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.39  Med: 9.61 Max: 29.16
Current: 16.71
6.39
29.16
Price-to-Intrinsic-Value-Projected-FCF 2.74
EW's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
53% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. EW: 2.74 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
EW' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.5  Med: 2.11 Max: 3.33
Current: 2.74
1.5
3.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.29
EW's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
88% of the 25 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. EW: 1.29 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.72
EW's Price-to-Median-PS-Value is ranked lower than
77% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. EW: 1.72 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EW' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.62 Max: 1.73
Current: 1.72
0.26
1.73
Price-to-Peter-Lynch-Fair-Value 1.78
EW's Price-to-Peter-Lynch-Fair-Value is ranked higher than
58% of the 57 Companies
in the Global Medical Devices industry.

( Industry Median: 1.61 vs. EW: 1.78 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
EW' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.4 Max: 3.13
Current: 1.78
0.68
3.13
Price-to-Graham-Number 5.22
EW's Price-to-Graham-Number is ranked lower than
74% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. EW: 5.22 )
Ranked among companies with meaningful Price-to-Graham-Number only.
EW' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.34  Med: 3.68 Max: 32.25
Current: 5.22
2.34
32.25
Earnings Yield (Greenblatt) % 4.42
EW's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. EW: 4.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EW' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.5  Med: 4.8 Max: 14.7
Current: 4.42
2.5
14.7
Forward Rate of Return (Yacktman) % 25.72
EW's Forward Rate of Return (Yacktman) % is ranked higher than
89% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. EW: 25.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
EW' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 15  Med: 22.8 Max: 37.4
Current: 25.72
15
37.4

More Statistics

Revenue (TTM) (Mil) $3,150
EPS (TTM) $ 3.01
Beta0.89
Short Percentage of Float1.18%
52-Week Range $81.12 - 121.75
Shares Outstanding (Mil)211.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,278 3,601 3,965
EPS ($) 3.38 3.84 4.37
EPS without NRI ($) 3.38 3.84 4.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.43%
Dividends per Share ($)
» More Articles for EW

Headlines

Articles On GuruFocus.com
Edwards Lifesciences To Present At The Deutsche Bank 42nd Annual Health Care Conference Apr 27 2017 
Edwards' Advanced Hemodynamic Monitoring Platform Receives FDA Clearance Apr 19 2017 
David Rolfe Comments on Edwards Lifesciences Apr 14 2017 
David Rolfe's Wedgewood Partners 1st Quarter 2017 Letter: Happy 8th Anniversary Mr. Market Apr 14 2017 
Edwards Lifesciences To Host Earnings Conference Call On April 25, 2017 Apr 10 2017 
Baron Opportunity Fund Comments on Edwards Feb 21 2017 
Edwards Lifesciences Director Buys 3,000 Shares Feb 07 2017 
12 Best Stocks for Value Investors This Week Feb 05 2017 
Weekly Top Insider Buys Highlight for the Week of Dec. 2 Dec 04 2016 
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 

More From Other Websites
Edwards Lifesciences To Present At The Deutsche Bank 42nd Annual Health Care Conference Apr 27 2017
Edited Transcript of EW earnings conference call or presentation 25-Apr-17 9:00pm GMT Apr 26 2017
Edwards Rockets To 6-Month High On Strong U.S. Heart-Valve Sales Apr 26 2017
The Hot Stock: Edwards Lifesciences Soars 11% Apr 26 2017
GLOBAL MARKETS-Stocks advance on earnings; Canada dollar, Mexico peso weaken on NAFTA news Apr 26 2017
Here's What's Pumping Up Shares of Edwards Lifesciences Corp. Today Apr 26 2017
Edwards Lifesciences (EW) Tops Q1 Earnings, Updates '17 View Apr 26 2017
Stocks Open Flat; Earnings Reports Trigger Early Breakouts Apr 26 2017
Early movers: BA, UTX, PG, TWTR, PEP, T, X, MCD, CMG & more Apr 26 2017
Edwards Lifesciences shares surge on earnings beat, outlook Apr 25 2017
Edwards Lifesciences beats Street 1Q forecasts Apr 25 2017
Edwards profit tops expectations on soaring heart valve sales Apr 25 2017
Edwards Lifesciences Reports First Quarter Results Apr 25 2017
Medical Product Stocks Earnings on Apr 25: SYK, EW, LH Apr 24 2017
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store? Apr 20 2017
Edwards' Advanced Hemodynamic Monitoring Platform Receives FDA Clearance Apr 19 2017
Canaccord Says Edwards Lifesciences Is Its Favorite Med Tech Stock Apr 17 2017
David Rolfe Comments on Edwards Lifesciences Apr 14 2017
Which Medtech Stocks Should You Buy Ahead Of Q1? Apr 13 2017
You Should Own J&J, Zimmer Biomet Ahead Of Earnings: RBC Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)